Erratum to: Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis (CardioVascular and Interventional Radiology, (2016), 39, 11, (1580-1588), 10.1007/s00270-016-1426-y)

Laila Lobo, Danny Yakoub, Omar Picado, Caroline Ripat, Fiorella Pendola, Rishika Sharma, Rana ElTawil, Deukwoo Kwon, Shree Venkat, Loraine Portelance, Raphael Yechieli

Research output: Contribution to journalComment/debate

Abstract

Corrections to the last section (“Survival”) on page 1582: Line: 7 Word: 3 TARE should be changed to TACE Word: 9 TACE should be changed to TARE Line: 10 Word: 4 TARE should be changed to TACE Line: 11 Word: 2 TACE should be changed to TARE Line: 13 Word: 6 TARE should be changed to TACE The complete corrected section appears below. Survival Survival information was extracted from the five studies. This included 284 patients undergoing TACE and 269 patients undergoing TARE. Male to female ratio for TACE is 82:18 and for TARE is 77:23. Median age for TACE is 63 with a range of 33–88, whereas TARE is 64 with range of 29–88. Overall survival at 1 year was 42% for TACE subjects compared to 46% for TARE. Statistically there was no difference noticed between 2 modalities (RR = 0.93, 95% CI 0.81–1.08, p = 0.33). At 2 years more TACE patients were alive than those that received TARE (27 vs. 18%) the difference of which was statistically significant (RR = 1.36, 95% CI 1.05–1.76, p = 0.02). At 3 years more TACE patients survived (14 vs.8%) yet no statistically significant difference was noted (RR = 1.27, 95% CI 0.88–1.84, p = 0.20). At 4 years subjects alive from both TACE and TARE were 4% with no statistically significant difference in survival (RR = 1.64, 95% CI 0.80–3.34, p = 0.17). At 5 years only 1% of subject population was alive from both TACE and TARE treatment modalities. There was minimal heterogeneity among studies (p[0.05). Disease-specific mortality (RR = 1.58, 95% CI 0.49–5.10, p = 0.44) did not show difference between studies but high heterogeneity was noted (π2 = 0.6462, p = 0.0015, I2 = 90%).

Original languageEnglish (US)
Number of pages1
JournalCardiovascular and Interventional Radiology
Volume40
Issue number9
DOIs
StatePublished - Sep 1 2017

Fingerprint

Interventional Radiology
Meta-Analysis
Hepatocellular Carcinoma
Survival
Mortality
Population

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

Erratum to : Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis (CardioVascular and Interventional Radiology, (2016), 39, 11, (1580-1588), 10.1007/s00270-016-1426-y). / Lobo, Laila; Yakoub, Danny; Picado, Omar; Ripat, Caroline; Pendola, Fiorella; Sharma, Rishika; ElTawil, Rana; Kwon, Deukwoo; Venkat, Shree; Portelance, Loraine; Yechieli, Raphael.

In: Cardiovascular and Interventional Radiology, Vol. 40, No. 9, 01.09.2017.

Research output: Contribution to journalComment/debate

Lobo, Laila ; Yakoub, Danny ; Picado, Omar ; Ripat, Caroline ; Pendola, Fiorella ; Sharma, Rishika ; ElTawil, Rana ; Kwon, Deukwoo ; Venkat, Shree ; Portelance, Loraine ; Yechieli, Raphael. / Erratum to : Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis (CardioVascular and Interventional Radiology, (2016), 39, 11, (1580-1588), 10.1007/s00270-016-1426-y). In: Cardiovascular and Interventional Radiology. 2017 ; Vol. 40, No. 9.
@article{25f23d3cf4684f9da9fe33fa9a5ecd6c,
title = "Erratum to: Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis (CardioVascular and Interventional Radiology, (2016), 39, 11, (1580-1588), 10.1007/s00270-016-1426-y)",
abstract = "Corrections to the last section (“Survival”) on page 1582: Line: 7 Word: 3 TARE should be changed to TACE Word: 9 TACE should be changed to TARE Line: 10 Word: 4 TARE should be changed to TACE Line: 11 Word: 2 TACE should be changed to TARE Line: 13 Word: 6 TARE should be changed to TACE The complete corrected section appears below. Survival Survival information was extracted from the five studies. This included 284 patients undergoing TACE and 269 patients undergoing TARE. Male to female ratio for TACE is 82:18 and for TARE is 77:23. Median age for TACE is 63 with a range of 33–88, whereas TARE is 64 with range of 29–88. Overall survival at 1 year was 42{\%} for TACE subjects compared to 46{\%} for TARE. Statistically there was no difference noticed between 2 modalities (RR = 0.93, 95{\%} CI 0.81–1.08, p = 0.33). At 2 years more TACE patients were alive than those that received TARE (27 vs. 18{\%}) the difference of which was statistically significant (RR = 1.36, 95{\%} CI 1.05–1.76, p = 0.02). At 3 years more TACE patients survived (14 vs.8{\%}) yet no statistically significant difference was noted (RR = 1.27, 95{\%} CI 0.88–1.84, p = 0.20). At 4 years subjects alive from both TACE and TARE were 4{\%} with no statistically significant difference in survival (RR = 1.64, 95{\%} CI 0.80–3.34, p = 0.17). At 5 years only 1{\%} of subject population was alive from both TACE and TARE treatment modalities. There was minimal heterogeneity among studies (p[0.05). Disease-specific mortality (RR = 1.58, 95{\%} CI 0.49–5.10, p = 0.44) did not show difference between studies but high heterogeneity was noted (π2 = 0.6462, p = 0.0015, I2 = 90{\%}).",
author = "Laila Lobo and Danny Yakoub and Omar Picado and Caroline Ripat and Fiorella Pendola and Rishika Sharma and Rana ElTawil and Deukwoo Kwon and Shree Venkat and Loraine Portelance and Raphael Yechieli",
year = "2017",
month = "9",
day = "1",
doi = "10.1007/s00270-017-1693-2",
language = "English (US)",
volume = "40",
journal = "CardioVascular and Interventional Radiology",
issn = "7415-5101",
publisher = "Springer Verlag",
number = "9",

}

TY - JOUR

T1 - Erratum to

T2 - Unresectable Hepatocellular Carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis (CardioVascular and Interventional Radiology, (2016), 39, 11, (1580-1588), 10.1007/s00270-016-1426-y)

AU - Lobo, Laila

AU - Yakoub, Danny

AU - Picado, Omar

AU - Ripat, Caroline

AU - Pendola, Fiorella

AU - Sharma, Rishika

AU - ElTawil, Rana

AU - Kwon, Deukwoo

AU - Venkat, Shree

AU - Portelance, Loraine

AU - Yechieli, Raphael

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Corrections to the last section (“Survival”) on page 1582: Line: 7 Word: 3 TARE should be changed to TACE Word: 9 TACE should be changed to TARE Line: 10 Word: 4 TARE should be changed to TACE Line: 11 Word: 2 TACE should be changed to TARE Line: 13 Word: 6 TARE should be changed to TACE The complete corrected section appears below. Survival Survival information was extracted from the five studies. This included 284 patients undergoing TACE and 269 patients undergoing TARE. Male to female ratio for TACE is 82:18 and for TARE is 77:23. Median age for TACE is 63 with a range of 33–88, whereas TARE is 64 with range of 29–88. Overall survival at 1 year was 42% for TACE subjects compared to 46% for TARE. Statistically there was no difference noticed between 2 modalities (RR = 0.93, 95% CI 0.81–1.08, p = 0.33). At 2 years more TACE patients were alive than those that received TARE (27 vs. 18%) the difference of which was statistically significant (RR = 1.36, 95% CI 1.05–1.76, p = 0.02). At 3 years more TACE patients survived (14 vs.8%) yet no statistically significant difference was noted (RR = 1.27, 95% CI 0.88–1.84, p = 0.20). At 4 years subjects alive from both TACE and TARE were 4% with no statistically significant difference in survival (RR = 1.64, 95% CI 0.80–3.34, p = 0.17). At 5 years only 1% of subject population was alive from both TACE and TARE treatment modalities. There was minimal heterogeneity among studies (p[0.05). Disease-specific mortality (RR = 1.58, 95% CI 0.49–5.10, p = 0.44) did not show difference between studies but high heterogeneity was noted (π2 = 0.6462, p = 0.0015, I2 = 90%).

AB - Corrections to the last section (“Survival”) on page 1582: Line: 7 Word: 3 TARE should be changed to TACE Word: 9 TACE should be changed to TARE Line: 10 Word: 4 TARE should be changed to TACE Line: 11 Word: 2 TACE should be changed to TARE Line: 13 Word: 6 TARE should be changed to TACE The complete corrected section appears below. Survival Survival information was extracted from the five studies. This included 284 patients undergoing TACE and 269 patients undergoing TARE. Male to female ratio for TACE is 82:18 and for TARE is 77:23. Median age for TACE is 63 with a range of 33–88, whereas TARE is 64 with range of 29–88. Overall survival at 1 year was 42% for TACE subjects compared to 46% for TARE. Statistically there was no difference noticed between 2 modalities (RR = 0.93, 95% CI 0.81–1.08, p = 0.33). At 2 years more TACE patients were alive than those that received TARE (27 vs. 18%) the difference of which was statistically significant (RR = 1.36, 95% CI 1.05–1.76, p = 0.02). At 3 years more TACE patients survived (14 vs.8%) yet no statistically significant difference was noted (RR = 1.27, 95% CI 0.88–1.84, p = 0.20). At 4 years subjects alive from both TACE and TARE were 4% with no statistically significant difference in survival (RR = 1.64, 95% CI 0.80–3.34, p = 0.17). At 5 years only 1% of subject population was alive from both TACE and TARE treatment modalities. There was minimal heterogeneity among studies (p[0.05). Disease-specific mortality (RR = 1.58, 95% CI 0.49–5.10, p = 0.44) did not show difference between studies but high heterogeneity was noted (π2 = 0.6462, p = 0.0015, I2 = 90%).

UR - http://www.scopus.com/inward/record.url?scp=85019766543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019766543&partnerID=8YFLogxK

U2 - 10.1007/s00270-017-1693-2

DO - 10.1007/s00270-017-1693-2

M3 - Comment/debate

AN - SCOPUS:85019766543

VL - 40

JO - CardioVascular and Interventional Radiology

JF - CardioVascular and Interventional Radiology

SN - 7415-5101

IS - 9

ER -